Table 1.
Demographics
| N=46 | |
|---|---|
| Age (y), mean (range) | 26.1 (15.0 – 35.9) |
| BMI, mean (range) | 24.0 (16.9 – 39.6) |
| Race-Caucasian, % (n) | 74 (34/46) |
| Education>College Graduate, % (n) | 59 (27/46) |
| Income>75k, % (n) | 37 (17/46) |
| Marital status-single, % (n) | 70 (32/46) |
| Previous pregnancy, % (n) | 24 (11/46) |
| Cancer Type and Regimen | |
| Breast, % (n) | 41 (19/46) |
| TCH | 26 (5/19) |
| TC | 21 (4/19) |
| ACT | 47 (9/19) |
| ECT | 5 (1/19) |
| Leukemia, % (n) | 9 (4/46) |
| Lymphoma, % (n) | 28 (13/46) |
| BEACOPP | 31 (4/13) |
| ABVD | 46 (6/13) |
| ABVE | 8 (1/13) |
| R-CHOP | 8 (1/13) |
| ICE | 8 (1/13) |
| Sarcoma, % (n) | 9 (4/46) |
| Brain, % (n) | 2 (1/46) |
| Wilm’s, % (n) | 2 (1/46) |
| Germ Cell, % (n) | 2 (1/46) |
| Other, % (n) | 4 (2/46) |
| Alkylating agent use, % (n) | 72 (33/46) |
| Alkylator score, mean (range) | 1.4 (0 – 4) |
| Using exogenous hormones, % (n) | 54 (25/46) |
| Combined oral contraceptives | 80 (20/25) |
| Vaginal ring (Nuvaring) | 12 (3/25) |
| Progestin IUD | 4 (1/25) |
| Lupron Depot | 4 (1/25) |
| Seen in early follicular phase, % (n) | 54 (25/46) |
| Self-reported cycle length (d), mean (range)* | 28 (21–32) |
*
For participants not taking exogenous hormones